Brand and Other Names:Detrol, Detrol LA
- Classes: Anticholinergics, Genitourinary
Dosing & Uses
Dosage Forms & Strengths
tablet, immediate release
capsule, extended release
Overactive Bladder, Urge Incontinence
Immediate release: 2 mg PO q12hr
Extended release: 2-4 mg PO once daily
- CrCl 10-30 mL/min: Not to exceed 1 mg PO q12hr (immediate release) or 2 mg PO once daily (extended release)
- CrCl <10 mL/min: Not recommended
- Mild to moderate (Child-Pugh class A or B): Not to exceed 1 mg PO q12hr (immediate release) or 2 mg PO once daily (extended release)
- Severe (Child-Pugh class C): Not recommended
Strong CYP3A4 inhibitors
- Not to exceed 1 mg PO q12hr (immediate release) or 2 mg PO once daily (extended release)
Serious - Use Alternative
Significant - Monitor Closely
Dry mouth (40%)
Urinary or gastric retention
Uncontrolled narrow-angle glaucoma
Hypersensitivity to drug or ingredients or to fesoterodine fumarate, which is metabolized to 5-hydroxymethyl tolterodine
Controlled narrow-angle glaucoma, bladder outflow obstruction, gastrointestinal obstruction, hepatic or renal impairment
Anaphylaxis and angioedema necessitating hospitalization and emergency treatment reported with first or subsequent doses
Anticholinergic central nervous system effects (eg, dizziness, somnolence) reported; patients should not drive or operate heavy machinery until they adjust to therapy
Use with caution in patients with myasthenia gravis, which is characterized by decreased cholinergic activity at neuromuscular junction
When coadministered with strong CYP3A4 inhibitors, tolterodine should be given at reduced dosage
Pregnancy & Lactation
Pregnancy category: C
Lactation: Unknown whether drug is distributed in breast milk; do not nurse
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Competitive muscarinic receptor antagonist; decreases bladder contractions; is more specific for bladder than oxybutynin
Onset: Overactive bladder, 1 wk; urge incontinence, 1 hr
Time to peak effect: 2-4 wk
Peak plasma time: Immediate release, 1-2 hr; extended release, 2-6 hr
Vd: 113 L
Metabolized in liver by CYP2D6 and (to minor extent) CYP3A4
Metabolites: 5-Hydroxymethyl, dealkylated tolterodine
Half-life: Parent drug, 1.9-3.7 hr; active metabolite (5-hydroxymethyl), 3 hr (8.7 hr in cirrhosis)
Total body clearance: 5.7 L/kg/hr
Excretion: Urine (77%), feces (17%)
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs